[go: up one dir, main page]

MA34227B1 - Procédé de préparation de compositions pharmaceutiques destinées à une administration orale, comprenant un ou plusieurs principes actifs, et compositions les comprenant - Google Patents

Procédé de préparation de compositions pharmaceutiques destinées à une administration orale, comprenant un ou plusieurs principes actifs, et compositions les comprenant

Info

Publication number
MA34227B1
MA34227B1 MA35363A MA35363A MA34227B1 MA 34227 B1 MA34227 B1 MA 34227B1 MA 35363 A MA35363 A MA 35363A MA 35363 A MA35363 A MA 35363A MA 34227 B1 MA34227 B1 MA 34227B1
Authority
MA
Morocco
Prior art keywords
compositions
same
active ingredients
oral administration
preparing pharmaceutical
Prior art date
Application number
MA35363A
Other languages
English (en)
Inventor
Axelle Lesot
Damia Leydet
Arnaud Moussel
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42797556&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34227(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA34227B1 publication Critical patent/MA34227B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/005—Coating of tablets or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Paints Or Removers (AREA)

Abstract

La présente invention porte sur un procédé d'« enrobage par fusion » de principes actifs pharmaceutiques, caractérisé par des propriétés organoleptiques ou physicochimiques qu'il est souhaitable de masquer. L'invention porte aussi sur les principes actifs médicaux obtenus, dont les propriétés organoleptiques ou physicochimiques ont été masquées, et sur les compositions qui les contiennent.
MA35363A 2010-04-21 2011-04-20 Procédé de préparation de compositions pharmaceutiques destinées à une administration orale, comprenant un ou plusieurs principes actifs, et compositions les comprenant MA34227B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1053034A FR2959130A1 (fr) 2010-04-21 2010-04-21 Procede de preparation de compositions pharmaceutiques destinees a l'administration par voie orale comprenant un ou plusieurs principes actifs et les compositions les comprenant.
PCT/IB2011/051736 WO2011132167A1 (fr) 2010-04-21 2011-04-20 Procédé de préparation de compositions pharmaceutiques destinées à une administration orale, comprenant un ou plusieurs principes actifs, et compositions les comprenant

Publications (1)

Publication Number Publication Date
MA34227B1 true MA34227B1 (fr) 2013-05-02

Family

ID=42797556

Family Applications (2)

Application Number Title Priority Date Filing Date
MA35363A MA34227B1 (fr) 2010-04-21 2011-04-20 Procédé de préparation de compositions pharmaceutiques destinées à une administration orale, comprenant un ou plusieurs principes actifs, et compositions les comprenant
MA35362A MA34226B1 (fr) 2010-04-21 2011-04-20 Composition à base de fexofènadine et procede de préparation pour celle-ci

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA35362A MA34226B1 (fr) 2010-04-21 2011-04-20 Composition à base de fexofènadine et procede de préparation pour celle-ci

Country Status (23)

Country Link
US (2) US20130251794A1 (fr)
EP (2) EP2560612B1 (fr)
JP (2) JP2013525341A (fr)
KR (2) KR20130094716A (fr)
CN (2) CN102946857A (fr)
AR (2) AR080934A1 (fr)
AU (2) AU2011244020A1 (fr)
BR (2) BR112012026596A2 (fr)
CA (2) CA2796821A1 (fr)
CL (2) CL2012002898A1 (fr)
CO (2) CO6620042A2 (fr)
EA (2) EA201291088A1 (fr)
ES (2) ES2525163T3 (fr)
FR (1) FR2959130A1 (fr)
IL (2) IL222576A0 (fr)
MA (2) MA34227B1 (fr)
MX (1) MX2012012275A (fr)
PH (2) PH12012502085A1 (fr)
PL (2) PL2560613T3 (fr)
SG (3) SG184951A1 (fr)
TW (2) TWI478713B (fr)
UY (2) UY33350A (fr)
WO (2) WO2011132167A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102349889B (zh) * 2011-11-01 2013-08-28 江苏先声药物研究有限公司 一种含有决奈达隆的组合物
JP5841433B2 (ja) * 2012-01-11 2016-01-13 日東電工株式会社 口腔内フィルム状基剤及び製剤
JP6245677B2 (ja) * 2012-01-20 2017-12-13 ニプロ株式会社 口腔内崩壊錠
JP6255908B2 (ja) * 2012-11-09 2018-01-10 大正製薬株式会社 固形製剤
FR2999937B1 (fr) * 2012-12-21 2015-01-09 Sanofi Sa Unite solide a haute teneur en fexofenadine et son procede de preparation
CN104274408A (zh) * 2013-07-10 2015-01-14 北京科信必成医药科技发展有限公司 一种熔融包衣的速释药物微粒及其制备方法
CN103610645B (zh) * 2013-11-25 2016-05-11 浙江万晟药业有限公司 一种非索非那定盐酸盐的药物组合物及制备方法
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
WO2016120299A1 (fr) * 2015-01-28 2016-08-04 Sanovel Ilac Sanayi Ve Ticaret A.S. Formulations de dronédarone à délitement buccal
WO2017093890A1 (fr) * 2015-11-30 2017-06-08 Piramal Enterprises Limited Formulation de comprimé à base de clobazam et son procédé de préparation
EP3363429A1 (fr) * 2017-02-20 2018-08-22 DSM IP Assets B.V. Procédé pour la production de particules enrobées
EP3670489A1 (fr) * 2018-12-21 2020-06-24 Dompé farmaceutici S.p.A. Co-cristal de kétoprofène, compositions le comprenant, son procédé de production et ses utilisations
EP3842408A1 (fr) 2019-12-23 2021-06-30 Dompé farmaceutici S.p.A. Co-cristal de kétoprofène et sa préparation, compositions pharmaceutiques le contenant et ses utilisations
JP2023549381A (ja) 2020-11-18 2023-11-24 バイオファーマ・シナジーズ，エス．エル． 抗ヒスタミン活性化合物を含む口内分散性粉末組成物
WO2022175829A1 (fr) 2021-02-17 2022-08-25 Cellix Bio Private Limited Formulations et compositions topiques
CA3242293A1 (fr) * 2021-12-29 2023-07-06 Opella Healthcare Group Sas Compositions contenant de la fexofenadine

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL193682C (nl) 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
JPH07100665B2 (ja) * 1987-12-23 1995-11-01 信越化学工業株式会社 被覆薬剤の製造方法
US5296236A (en) * 1988-09-16 1994-03-22 Recordati S.A., Chemical And Pharmaceutical Company Controlled release therapeutic system for a liquid pharmaceutical formulations
KR100187540B1 (ko) * 1990-11-30 1999-06-01 오노다 마사요시 속방성 피복 제제 및 이의 제조방법
US5578322A (en) * 1990-11-30 1996-11-26 Yamanouchi Pharmaceutical Co., Ltd. Quick release coated preparation
EP0664701B1 (fr) * 1992-10-16 1997-09-10 Glaxo Group Limited Compositions a base de ranitidine masquant le gout de celle-ci
KR100405116B1 (ko) 1995-02-28 2004-02-05 아벤티스 파마슈티칼스 인크. 피페리디노알칸올화합물에대한약제학적조성물
WO1997001798A1 (fr) * 1995-06-29 1997-01-16 Eastman Kodak Company Support de transfert et procede de fusion d'une image transferable et d'un disque numerique
IT1276160B1 (it) * 1995-11-22 1997-10-27 Recordati Chem Pharm Composizioni farmaceutiche orali a pronto rilascio per sospensioni estemporanee
FR2753904B1 (fr) * 1996-10-01 1998-10-30 Gattefosse Ets Sa Composition pharmaceutique a liberation modifiee de principe actif, comportant une matrice, et procede de fabrication
US5891476A (en) * 1997-12-22 1999-04-06 Reo; Joe P. Tastemasked pharmaceutical system
US6274162B1 (en) * 2000-01-14 2001-08-14 Bpsi Holdings, Inc. Elegant film coating system
FR2811912B1 (fr) * 2000-07-21 2003-02-07 Gattefosse Ets Sa Procede d'enrobage de particules solides par un agent thermofusible, et particules solides ainsi enrobees
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
FR2838647B1 (fr) * 2002-04-23 2006-02-17 Particules enrobees a liberation prolongee, leur procede de preparation et comprimes les contenant
EP1542659A4 (fr) * 2002-08-14 2008-03-26 Du Pont Procede d'enrobage d'une particule pharmaceutique
FR2848855B1 (fr) 2002-12-23 2005-02-11 Aventis Pharma Sa Compositions pour administration orale de principes actifs necessitant un masquage du gout
DE60308828T2 (de) * 2003-05-20 2007-05-24 Ethypharm Orale pharmazeutische Zusammensetzung mit verzögerter Freisetzung
FR2857263B1 (fr) * 2003-07-09 2005-09-09 Sanofi Synthelabo Nouvelle composition pharmaceutique solide comprenant de l'amisulpride
WO2005065639A2 (fr) * 2003-11-21 2005-07-21 Torrent Pharmaceuticals Limited Nouvelles compositions pharmaceutiques
WO2005062722A2 (fr) * 2003-11-21 2005-07-14 Sun Pharmaceutical Industries Limited Composition pharmaceutique orale
ATE446086T1 (de) 2004-03-19 2009-11-15 Zentiva Kimyasal Ueruenler San Herstellung von lipid-beschichtetem cefuroxime axetil
US20070048373A1 (en) * 2005-08-30 2007-03-01 Cima Labs Inc. Dried milled granulate and methods

Also Published As

Publication number Publication date
TW201204415A (en) 2012-02-01
MX2012012275A (es) 2012-11-16
PH12012502084A1 (en) 2013-02-04
CL2012002909A1 (es) 2013-01-25
CL2012002898A1 (es) 2013-03-01
TWI478713B (zh) 2015-04-01
CO6620042A2 (es) 2013-02-15
UY33350A (es) 2011-12-01
JP2013525340A (ja) 2013-06-20
AU2011244020A1 (en) 2012-11-08
CO6620043A2 (es) 2013-02-15
WO2011151733A2 (fr) 2011-12-08
KR20130080428A (ko) 2013-07-12
FR2959130A1 (fr) 2011-10-28
CA2796816A1 (fr) 2011-12-08
PL2560613T3 (pl) 2015-03-31
EP2560612B1 (fr) 2014-09-03
CN102946857A (zh) 2013-02-27
AU2011262319A1 (en) 2012-11-08
WO2011151733A3 (fr) 2012-01-26
MA34226B1 (fr) 2013-05-02
PL2560612T3 (pl) 2015-03-31
CN103002874B (zh) 2015-04-08
EA201291088A1 (ru) 2013-03-29
WO2011132167A1 (fr) 2011-10-27
CA2796821A1 (fr) 2011-10-27
EP2560612A1 (fr) 2013-02-27
EP2560613B1 (fr) 2014-10-15
IL222576A0 (en) 2012-12-31
BR112012026596A2 (pt) 2016-07-12
BR112012026938A2 (pt) 2017-10-03
EA201291089A1 (ru) 2013-05-30
IL222578A0 (en) 2012-12-31
JP2013525341A (ja) 2013-06-20
SG184950A1 (en) 2012-11-29
SG10201506708UA (en) 2015-09-29
UY33351A (es) 2011-12-01
KR20130094716A (ko) 2013-08-26
ES2527390T3 (es) 2015-01-23
ES2525163T3 (es) 2014-12-18
PH12012502085A1 (en) 2013-02-04
US20130183382A1 (en) 2013-07-18
AR081539A1 (es) 2012-10-03
EP2560613A2 (fr) 2013-02-27
US20130251794A1 (en) 2013-09-26
CN103002874A (zh) 2013-03-27
SG184951A1 (en) 2012-11-29
TW201206434A (en) 2012-02-16
AR080934A1 (es) 2012-05-16

Similar Documents

Publication Publication Date Title
MA34227B1 (fr) Procédé de préparation de compositions pharmaceutiques destinées à une administration orale, comprenant un ou plusieurs principes actifs, et compositions les comprenant
PH12020550341A1 (en) Niraparib formulations
MX2022002592A (es) Conjugado de anticuerpo-farmaco que comprende un anticuerpo contra el gen del receptor huerfano 1 similar a tirosina cinasa receptora (ror1) humano y uso para el mismo.
TN2012000074A1 (fr) Derives de thieno [2, 3-b] pyridine servant d'inhibiteurs de replication virale
JOP20220131A1 (ar) مركبات أمينو كينولون تحمل بدائل تستخدم كمثبطات لـ dgkalpha من أجل تنشيط المناعة
WO2015120110A3 (fr) Nouvelles formulations pharmaceutiques
MX2012007410A (es) Compuestos antivirales novedosos.
EP4360713A3 (fr) Derives de quinazoline utilises comme agents antitumoraux
MA34727B1 (fr) Imidazolylimidazoles condensés utilisés comme composés antiviraux
NZ780890A (en) Pharmaceutical compositions comprising meloxicam
MX388457B (es) Inhibidores de imidazopirazina de la tirosina cinasa de bruton.
MX2010014057A (es) Compuestos de piridina.
MX2021011811A (es) Protacs que degradan el receptor de estrogeno.
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
IN2014MN00139A (fr)
MX344787B (es) Composiciones que contienen berberina o analogos de la misma para tratar rosacea o trastornos de la piel relacionados con enrojecimiento de la cara.
WO2017083304A8 (fr) Compositions thérapeutiques pour le traitement du virus de l'immunodéficience humaine
TNSN06439A1 (fr) Derives de 2-carbamide -4-phenylthiazole, leur preparation et leur application en therapeutique
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
EP4282414A3 (fr) Formulations de comprimés à libération modifiée contenant des inhibiteurs de phosphodiestérase
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
MX2013002649A (es) Agente terapeutico contra el dolor.
EP3639859A4 (fr) Composition pour l'administration d'un médicament par voie orale contenant de l'oxaliplatine et son procédé de préparation
MA33979B1 (fr) Piperazines en tant qu'agents antipaludiques